Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.